Mirtron-mediated RNA knockdown/replacement therapy for the treatment of dominant retinitis pigmentosa. (2021)
Attributed to:
Development of retinal gene therapy to treat dominantly inherited disease using a novel RNA-based silencing system
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41467-021-25204-3
PubMed Identifier: 34400638
Publication URI: http://europepmc.org/abstract/MED/34400638
Type: Journal Article/Review
Volume: 12
Parent Publication: Nature communications
Issue: 1
ISSN: 2041-1723